Patents by Inventor Jean-Sébastien Garrigue
Jean-Sébastien Garrigue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230320979Abstract: An oil-in-water emulsion for intravitreal administration, especially injection, including an active ingredient, an oil, a mixture of two non-ionic surfactants and water, the emulsion having a droplet size ranging from about 100 to about 200 nm. The emulsion avoids troubles of vision after administration into the vitreous body. The emulsion provides good therapeutic activity of the active ingredient for treating eye diseases or conditions, such as an eye disease or condition of the posterior segment of the eye.Type: ApplicationFiled: September 15, 2021Publication date: October 12, 2023Applicant: SANTEN SASInventors: Mathieu SCHMITT, Philippe DAULL, Jean-Sébastien GARRIGUE
-
Patent number: 11452739Abstract: The use of a polysaccharide derived from a bacterial strain in the prevention of ocular diseases and the treatment of ocular diseases. Especially, the ophthalmic use of a polysaccharide susceptible to be obtained from the CNCM I-5038 Cobetia marina bacterial strain in ocular conditions associated with ophthalmic dryness and ophthalmic inflammation.Type: GrantFiled: March 26, 2019Date of Patent: September 27, 2022Assignee: SANTEN SASInventors: Jennifer Dourlat, Philippe Daull, Jean-Sébastien Garrigue
-
Publication number: 20210106610Abstract: The use of a polysaccharide derived from a bacterial strain in the prevention of ocular diseases and the treatment of ocular diseases. Especially, the ophthalmic use of a polysaccharide susceptible to be obtained from the CNCM I-5038 Cobetia marina bacterial strain in ocular conditions associated with ophthalmic dryness and ophthalmic inflammation.Type: ApplicationFiled: March 26, 2019Publication date: April 15, 2021Applicant: SANTEN SASInventors: Jennifer DOURLAT, Philippe DAULL, Jean-Sébastien GARRIGUE
-
Patent number: 9682147Abstract: The present invention relates to a self-preserved oil dispersion. Especially, the present invention relates to a self-preserved oil dispersion including a dispersed oil phase, an aqueous phase and at least one surfactant, wherein said oil dispersion comprises boric acid in an amount ranging from 0.005% to 0.075% in weight of the total weight of the oil dispersion, said amount of boric acid being a preservative effective amount so that the oil dispersion has a preservative activity.Type: GrantFiled: February 22, 2013Date of Patent: June 20, 2017Assignee: SANTEN SASInventors: Jean-Sébastien Garrigue, Frédéric Lallemand, Betty Philips
-
Publication number: 20170165368Abstract: Composition comprising at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, said composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably comprised between 0.90 and 1, or a density above 1 more preferably between 1 and 1.5; having a surface tension of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not susceptible to emulsify into droplets when injected; method for treating a retinal disorder involving the use of said composition.Type: ApplicationFiled: February 23, 2017Publication date: June 15, 2017Inventors: Jean-Sebastien Garrigue, Frederic Lallemand, Jeffrey Heier
-
Patent number: 9616016Abstract: A composition includes at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, the composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably between 0.90 and 1, or a density above 1, more preferably between 1 and 1.5; having a surface tension of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not susceptible to emulsify into droplets when injected; method for treating a retinal disorder involving the use of the composition.Type: GrantFiled: November 19, 2010Date of Patent: April 11, 2017Assignee: SANTEN SASInventors: Frédéric Lallemand, Jean-Sébastien Garrigue, Jeffrey Heier
-
Patent number: 9555045Abstract: A composition for use in treating corneal and conjunctival lesions, includes a prostaglandin F2alpha or analogue, in a therapeutic amount, the composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative. A method for treating surface ocular conditions in a patient in need thereof, includes administering an effective amount of the composition.Type: GrantFiled: November 19, 2010Date of Patent: January 31, 2017Assignee: SANTEN SASInventors: Jean-Sebastien Garrigue, Frederic Lallemand, Philippe Daull, Christophe Baudouin
-
Publication number: 20160331683Abstract: A composition is described herein for administering with a sustained release kinetic a therapeutically effective amount of a therapeutic agent to a subject in need thereof for treating diseases or conditions of the eye, wherein the composition is an water-in-oil type emulsion comprising an oil phase, a lipophilic surfactant dissolved in the oil phase, an aqueous phase dispersed in the oil phase, a hydrophilic therapeutic agent dissolved in the aqueous dispersed phase, and wherein the composition is intraocularly injectable, wherein the composition has a density lower than 1. Some embodiments also relate to a pharmaceutical composition or to a medicament comprising a composition described herein, and to a method for treating a condition or disease of the eye comprising administering a therapeutic amount of a composition described herein.Type: ApplicationFiled: June 27, 2016Publication date: November 17, 2016Inventors: Frédéric LALLEMAN, Jean-Sébastien GARRIGUE
-
Patent number: 9107822Abstract: The invention relates to a composition for administering with a sustained release kinetic a therapeutically effective amount of a therapeutic agent to a subject in need thereof for treating diseases or conditions of the eye, wherein the composition is an water-in-oil type emulsion comprising an oil phase, a lipophilic surfactant dissolved in the oil phase, an aqueous phase dispersed in the oil phase, a hydrophilic therapeutic agent dissolved in the aqueous dispersed phase, and wherein the composition is intraocularly injectable, wherein the composition has a density lower than 1. The invention also relates to a pharmaceutical composition or to a medicament comprising the composition of the invention, and to a method for treating a condition or disease of the eye comprising administering a therapeutic amount of the composition of the invention. The invention also relates to a device comprising the composition of the invention.Type: GrantFiled: September 2, 2011Date of Patent: August 18, 2015Assignee: SANTEN SASInventors: Frederic Lallemand, Jean-Sebastien Garrigue, Betty Philips
-
Patent number: 9089480Abstract: A colloidal anionic oil-in-water emulsion includes a prostaglandin, an oil having a iodine value ?2, a surfactant and water, provided the anionic oil-in-water emulsion does not contain polyvinyl alcohol. The use of the anionic oil-in-water emulsions for enhancing the stability of the prostaglandins, for the treatment of ocular hypertension and/or glaucoma, for promoting growth of eyelashes and/or for treating eyelash hypotrichosis is also described.Type: GrantFiled: March 4, 2010Date of Patent: July 28, 2015Assignee: SANTEN SASInventors: Frederic Lallemand, Betty Phillips, Jean-Sebastien Garrigue
-
Patent number: 9072750Abstract: The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative; the invention also relates to a method for treating surface ocular conditions in a patient in need thereof, comprising administering a composition of the invention.Type: GrantFiled: November 19, 2010Date of Patent: July 7, 2015Assignee: SANTEN SASInventors: Jean-Sébastien Garrigue, Frédéric Lallemand, Philippe Daull, Christophe Baudouin
-
Publication number: 20150025020Abstract: The present invention relates to a self-preserved oil dispersion. Especially, the present invention relates to a self-preserved oil dispersion including a dispersed oil phase, an aqueous phase and at least one surfactant, wherein said oil dispersion comprises boric acid in an amount ranging from 0.005% to 0.075% in weight of the total weight of the oil dispersion, said amount of boric acid being a preservative effective amount so that the oil dispersion has a preservative activity.Type: ApplicationFiled: February 22, 2013Publication date: January 22, 2015Inventors: Jean-Sébastien Garrigue, Frédéric Lallemand, Betty Philips
-
Patent number: 8512687Abstract: Oil-in-water emulsion including a non-steroidal anti-inflammatory drug and a quaternary ammonium halide useful for the prevention and treatment of inflammation in the eye, and process for manufacturing thereof.Type: GrantFiled: July 29, 2010Date of Patent: August 20, 2013Assignee: Novagali Pharma SAInventors: Grégory Lambert, Laura Rabinovich-Guilatt, Frédéric Lallemand, Jean-Sébastien Garrigue, Betty Philips
-
Publication number: 20130164285Abstract: The invention relates to a composition for administering with a sustained release kinetic a therapeutically effective amount of a therapeutic agent to a subject in need thereof for treating diseases or conditions of the eye, wherein the composition is an water-in-oil type emulsion comprising an oil phase, a lipophilic surfactant dissolved in the oil phase, an aqueous phase dispersed in the oil phase, a hydrophilic therapeutic agent dissolved in the aqueous dispersed phase, and wherein the composition is intraocularly injectable, wherein the composition has a density lower than 1. The invention also relates to a pharmaceutical composition or to a medicament comprising the composition of the invention, and to a method for treating a condition or disease of the eye comprising administering a therapeutic amount of the composition of the invention. The invention also relates to a device comprising the composition of the invention.Type: ApplicationFiled: September 2, 2011Publication date: June 27, 2013Applicant: NOVAGALI PHARMA SAInventors: Frederic Lallemand, Jean-Sebastien Garrigue, Betty Philips
-
Patent number: 8372434Abstract: An ophthalmic oil-in-water type emulsion, which includes colloid particles having an oily core surrounded by an interfacial film, the emulsion including at least one cationic agent, at least one no ionic surfactant, the emulsion having a positive zeta potential and meeting zeta potential stability Test A requirements. Process for making the emulsions. Delivery device selected from the group including lenses, ocular patch, implant, insert, the device containing an emulsion according to the invention.Type: GrantFiled: October 10, 2005Date of Patent: February 12, 2013Assignee: Novagali Pharma SAInventors: Séverine Bague, Betty Philips, Laura Rabinovich-Guilatt, Gregory Lambert, Jean-Sébastien Garrigue
-
Patent number: 8298568Abstract: A well tolerated oil-in-water emulsion useful as a delivery vehicle of hydrophobic ingredients such as pharmaceutical drugs, wherein the emulsion particles have a net positive charge and comprises 0.001 to 0.1% of a cationic agent, 0 to 1% of a non ionic surfactant and 0 to 0.5% of an anionic surfactant.Type: GrantFiled: November 18, 2004Date of Patent: October 30, 2012Assignee: Novagali Pharma SAInventors: Séverine Bague, Betty Philips, Jean-Sébastien Garrigue, Laura Rabinovich-Guilatt, Gregory Lambert
-
Publication number: 20120238536Abstract: Composition comprising at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, said composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably comprised between 0.90 and 1, or a density above 1 more preferably between 1 and 1.5; having a surface tension of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not susceptible to emulsify into droplets when injected; method for treating a retinal disorder involving the use of said composition.Type: ApplicationFiled: November 19, 2010Publication date: September 20, 2012Applicant: NOVAGALI PHARMA SAInventors: Jean-Sebastien Garrigue, Frederic Lallemand, Jeffrey Heier
-
Publication number: 20120225939Abstract: The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative; the invention also relates to a method for treating surface ocular conditions in a patient in need thereof, comprising administering a composition of the invention.Type: ApplicationFiled: November 19, 2010Publication date: September 6, 2012Applicant: NOVAGALI PHARMA SAInventors: Jean-Sebastien Garrigue, Frederic Lallemand, Philippe Daull, Christophe Baudouin
-
Publication number: 20120058187Abstract: A composition is described herein for administering with a sustained release kinetic a therapeutically effective amount of a therapeutic agent to a subject in need thereof for treating diseases or conditions of the eye, wherein the composition is an water-in-oil type emulsion comprising an oil phase, a lipophilic surfactant dissolved in the oil phase, an aqueous phase dispersed in the oil phase, a hydrophilic therapeutic agent dissolved in the aqueous dispersed phase, and wherein the composition is intraocularly injectable, wherein the composition has a density lower than 1. Some embodiments also relate to a pharmaceutical composition or to a medicament comprising a composition described herein, and to a method for treating a condition or disease of the eye comprising administering a therapeutic amount of a composition described herein.Type: ApplicationFiled: September 3, 2010Publication date: March 8, 2012Applicant: NOVAGALI PHARMA SAInventors: Frédéric LALLEMAND, Jean-Sébastien GARRIGUE
-
Publication number: 20110319488Abstract: A colloidal anionic oil-in-water emulsion includes a prostaglandin, an oil having a iodine value ?2, a surfactant and water, provided the anionic oil-in-water emulsion does not contain polyvinyl alcohol. The use of the anionic oil-in-water emulsions for enhancing the stability of the prostaglandins, for the treatment of ocular hypertension and/or glaucoma, for promoting growth of eyelashes and/or for treating eyelash hypotrichosis is also described.Type: ApplicationFiled: March 4, 2010Publication date: December 29, 2011Applicant: NOVAGALI PHARMA SAInventors: Frederic Lallemand, Betty Phillips, Jean-Sebastien Garrigue